Novel Clones of *Streptococcus pneumoniae* Causing Invasive Disease in Malaysia

Johanna M. Jefferies¹,²,³, Mohd Yasim Mohd Yusof², Shamala Devi Sekaran³, Stuart C. Clarke¹,²,³,⁴,⁵

¹ Faculty of Medicine and Institute of Life Sciences, University of Southampton, Southampton, United Kingdom, ² NIHR Southampton Respiratory Biomedical Research Unit, Southampton, United Kingdom, ³ Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ⁴ Public Health England, Southampton, United Kingdom, ⁵ University of Southampton Malaysia Campus, Nusajaya, Malaysia

Abstract

Although *Streptococcus pneumoniae* is a leading cause of childhood disease in South East Asia, little has previously been reported regarding the epidemiology of invasive pneumococcal disease in Malaysia and very few studies have explored pneumococcal epidemiology using multilocus sequence typing (MLST). Here we describe serotype, multilocus sequence type (ST), and penicillin susceptibility of thirty pneumococcal invasive disease isolates received by the University of Malaya Medical Centre between February 2000 and January 2007 and relate this to the serotypes included in current pneumococcal conjugate vaccines. A high level of diversity was observed: fourteen serotypes and 26 sequence types (ST), (11 of which were not previously described) were detected from 30 isolates. Penicillin non-susceptible pneumococci accounted for 33% of isolates. The extent of molecular heterogeneity within carried and disease-causing Malaysian pneumococci remains unknown. Larger surveillance and epidemiological studies are now required in this region to provide robust evidence on which to base future vaccine policy.

Introduction

*Streptococcus pneumoniae* (the pneumococcus) remains a leading cause of pneumonia and invasive disease worldwide and cause significant morbidity and mortality, particularly in young children and the elderly. Pneumococci can be divided into 94 serotypes on the basis of their reactions with serum antibodies [1–4] and further differentiated into more than 8900 clonal types by mult locus sequence typing (MLST). Although the population of *S. pneumoniae* is very diverse, most disease worldwide is caused by around 10 serotypes [5]. There is little recent data on the epidemiology of invasive pneumococcal disease (IPD) in Malaysia; the majority of the few studies published to date have addressed serotype and/or antibiotic susceptibility [6–11]. A study describing clinical syndromes associated with childhood IPD during 1994–2000 was published in 2007, but does not include serotype information [12].

The heptavalent conjugate vaccine (Prevnar, PCV7, Pfizer) is effective against seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) responsible for much paediatric IPD in many western countries and elsewhere [13,14]. PCV7 was licensed in Malaysia in 2006, and 13-valent vaccine (Prevnar-13, PCV13, Pfizer) containing additional polysaccharides against serotypes 1, 3, 5, 7F, 16F and 19A was licensed in 2010. In addition, a 10-valent vaccine in which pneumococcal polysaccharides are conjugated to a *Haemophilus influenzae* surface protein has recently been licensed (PHID-CV, Synflorix, GSK). However, no pneumococcal conjuga-
Materials and Methods

The isolates used in this study were collected at University Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. UMMC is a large (>1200 beds), multi-disciplinary, city hospital serving Kuala Lumpur and the state of Selangor, which are the most economically developed areas of Malaysia. Individuals using the services of UMMC are mainly those from lower-middle and low-income groups due to the presence of a number of private medical centres in the area, serving mainly the upper-middle and upper income groups.

IPD was defined according to the Centers for Disease Control definition as isolation of *S. pneumoniae* from a normally sterile body site (e.g., blood, cerebrospinal fluid, or, less commonly, joint, pleural or pericardial fluid). Isolates were originally isolated from culture of invasive site clinical specimens including blood, cerebrospinal fluid (CSF) and pleural fluid, by culturing on 5% horse blood agar and incubation at 37°C in the presence of 5% CO2 for 12–15 hours. Alpha-haemolytic colonies were sub-cultured and confirmed as *S. pneumoniae* by their colony morphology, inability to produce catalase, ethylhydrocupreine hydrochloride (optochin) sensitivity and bile-solubility. Single colony picks were stored at −80°C in BHI broth supplemented with 10% (v/v) glycerol. The thirty pneumococcal isolates included in the study represent all viable after retrieval from ultra-cold storage from a total of 57 IPD isolates processed by UMMC during the period February 2000 to January 2007.

For this study, pneumococci were sub-cultured from frozen stocks onto 5% horse blood Columbia agar in the presence of an optochin disc. Serotyping was performed by traditional phenotypic (serological) methods and confirmed by multiplex-PCR (MP-PCR) [20].

Genotyping was performed using multi-locus sequence typing (MLST) by Qiagen Genomic Services (Hilden, Germany [21]. Briefly, ~500 bp fragments of seven housekeeping genes were produced, compared to a database of reference sequences (http://spneumoniae.mlst.net/) and assigned an allele number. A sequence type (ST) was then assigned to each unique combination of seven allele numbers. Previously unreported alleles were assigned a new allele number by submitting raw sequence data for forward and backward DNA strands to the database curator. New combinations of previously reported alleles were assigned a new ST by the curator on submission of serotype and other isolate-specific metadata. All previously unreported STs identified in this study were deposited in the MLST database. The isolate relationships between ST were defined using eBURST version 3 [22]. Clonal Complexes (CC) were analysed in order to understand relationships between pneumococci and for comparison with pneumococci reported form elsewhere. CC were defined as groups of ST sharing six or more identical housekeeping alleles. Susceptibility to penicillin and erythromycin were determined by the E-test method [23] and susceptibility reported according to British Society for Antimicrobial Chemotherapy (BSAC) breakpoints; Penicillin S = <0.06 mg/L, I = 0.12–1 mg/L and R = > 2 mg/L. Erythromycin breakpoint; R = >0.5 mg/L [24].

Results

Of the 30 IPD isolates included in the study, eleven were from children aged less than 15 years and seventeen were from adults. No date of birth or age was recorded for the remaining two isolates. (Table 1). Information regarding the PCV vaccination status of patients was not available. Twenty-six isolates were from blood, two from cerebrospinal fluid (CSF) and two from pleural...
### Table 1. Isolates used in this study.

| studyID | Specimen date | Age (yr) | Source         | Serotype | ST      | PCV7 | PHID-CV | PCV13 |
|---------|---------------|----------|----------------|----------|---------|------|---------|-------|
| 25      | 14/10/02      | <1 mo    | Blood          | 3        | 3798    | No   | Yes     | Yes   |
| 80A     | 21/9/03       | 6 mo     | Blood          | 6A       | 473     | No   | No      | No    |
| 9       | 25/7/02       | 1        | Blood          | 15A      | 3801    | No   | No      | No    |
| 74A     | 18/9/06       | 2        | Blood          | 9V       | 4128    | Yes  | Yes     | Yes   |
| 64      | 05/11/03      | 4        | Blood          | 11A      | 62      | No   | No      | No    |
| R98     | 07/11/00      | 6        | Blood          | 3F       | 83      | Yes  | Yes     | Yes   |
| 57      | 31/12/01      | 6        | Blood          | 19F      | 236     | Yes  | Yes     | Yes   |
| 91      | 11/02/03      | 9        | Blood          | 6A       | 3802    | No   | No      | No    |
| 87A     | 18/10/06      | 10       | Blood          | 19F      | 81      | Yes  | Yes     | Yes   |
| 43A     | 04/03/06      | 13       | Blood          | 23F      | 271     | Yes  | Yes     | Yes   |
| 70A     | 13/8/06       | 14       | Blood          | 23F      | 3800    | Yes  | Yes     | Yes   |
| 848     | 03/07/00      | 20       | Blood          | 19F      | 236     | Yes  | Yes     | Yes   |
| 29      | 24/10/02      | 20       | Blood          | 4        | 4127    | Yes  | Yes     | Yes   |
| 564     | 15/3/00       | 23       | Blood          | 18C      | 113     | n/a  | n/a     | n/a   |
| 63      | 05/09/03      | 25       | Blood          | 16F      | 3799    | No   | No      | No    |
| 27A     | 03/07/06      | 30       | Blood          | 34       | 3783    | No   | No      | No    |
| 110A    | 17/1/07       | 36       | Blood          | 19F      | 236     | Yes  | Yes     | Yes   |
| 17A     | 20/12/06      | 43       | Blood          | 19A      | 3781    | No   | No      | Yes   |
| 58A     | 14/7/06       | 50       | Blood          | 19A      | 199     | No   | No      | Yes   |
| 59A     | 14/7/06       | 50       | Pleural fluid  | 19A      | 199     | No   | No      | Yes   |
| 33A     | 20/3/06       | 52       | Blood          | 3        | 458     | No   | No      | Yes   |
| 33      | 07/11/02      | 53       | Blood          | 19F      | 81      | Yes  | Yes     | Yes   |
| 12      | 13/9/02       | 62       | Blood          | 6B       | 3797    | Yes  | Yes     | Yes   |
| 23      | 07/10/02      | 72       | Blood          | 9V       | 162     | Yes  | Yes     | Yes   |
| 60A     | 23/7/06       | 73       | Blood          | 14       | 124     | Yes  | Yes     | Yes   |
| 66      | 16/5/03       | 74       | Blood          | 4        | 3784    | Yes  | Yes     | Yes   |
| 16      | 22/2/2002     | 87       | Blood          | 14       | 156     | Yes  | Yes     | Yes   |
| 93A     | 11/09/06      | 88       | Blood          | 14       | 200     | Yes  | Yes     | Yes   |
| 18A     | 20/2/06       | unknown  | Blood          | 4        | 2213    | Yes  | Yes     | Yes   |
| 23A     | 03/03/06      | unknown  | CSF            | 9N       | 3782    | n/a  | n/a     | n/a   |

**Percent PCV coverage (assuming no cross protection between serotypes within a serogroup).**

Newly-assigned ST are shown in bold typeface.

doi:10.1371/journal.pone.0097912.t001
fluid. Fifteen different serotypes were detected among the 30 isolates (Table 1). Of these serotypes 19F was the most common (n = 5, 16.7%) followed by 4, 14, 19A and 23F and (n = 3, 10%) each. Twenty-six different ST, were observed among the 30 isolates (Table 1), 11 of which (49%) were novel at the time of analysis. When compared against the ST deposited in the S. pneumoniae MLST database (http://spneumoniae.mlst.net/) interrogated 26th July 2013, all of the 15 non-novel ST in this study had previously been observed with the same serotype as that detected here.

When relationships between ST were analysed using eBURST [22], we observed 16 clonal complexes (CC), 14 of which were able to be assigned a founder ST and 6 singleton ST (Figure 1). Of the 11 ST that were reported for the first time during this study, six (ST 3782, 3797, 3799, 3801, 3802 and 4128) were singleton ST, that is they did not share 6 or more housekeeping alleles with any other pneumococcus registered on the database at the time of writing (last accessed 26.07.2013). The remaining five newly assigned ST belong to five different CCs (Supplementary Figures S1–S14).

Ten isolates (33%) were penicillin-non-susceptible according to BSAC breakpoints, MICs ranged from 0.003 to 1.000 mg/L. None of the isolates in this study demonstrated full resistance to penicillin as defined by an MIC of >1 mg/L. Penicillin non-susceptible strains accounted for 53% (9/17) of PCV7 serotypes, non-susceptibility was confined to serotypes 14 (ST200, ST156), 19F (ST236, ST81) and 23F (ST83, ST271, ST3800) which are all included in PCV7, PHID-CV and PCV13. All but one of the penicillin non-susceptible strains were also resistant to erythromycin.

Seventeen (57%) of the isolates were of serotypes included in PCV7, three isolates were of vaccine-related serotype 19A. There was no increase in coverage with PHID-CV which includes serotypes 1, 5, and 7F in addition to those serotypes included in PCV7. PCV13, which further includes serotypes 3, 19A and 18F has coverage of 22 (73%) of the isolates included in this study.

**Discussion**

This study is among the first to characterise invasive pneumococcal isolates from Malaysia by both serotype and ST. Although we characterised only a relatively small number of isolates from one centre, we can demonstrate the presence of previously unreported ST in Malaysia. Of the 26 different ST identified, nearly half (n = 11) were novel of these newly-assigned ST, five were novel combinations of alleles, which may have arisen from recombination events and six included novel alleles not previously observed (3 strains had novel gdh alleles and 3 strains novel xpt alleles). The majority of ST observed in our study mapped to the main large clonal complexes when analysed by eBURST demonstrating that globally prevalent clones are represented in our dataset (Figure 1); however, the presence of a relatively large number of newly recognised ST in a small sample may suggest that the circulating population of pneumococci in Malaysia differs from those regions such as the USA and Europe which contribute more heavily to the database.

In our collection of isolates, serotype 19F was most common, which is in agreement with other recent reports from Malaysia and other South East Asian countries [25] that 19F is among the most common serotypes. Other common serotypes being 19A, 14 and 6B [10,26,27] This observation also agrees with serotypes reported from other with data from Association of South East Asian Nations (ASEAN) isolates deposited on the MLST database (23F n = 51 (14%), 19A n = 44 (12%), 19F n = 40 (11%)). In this study ST236
contributed to the prevalence of serotype 19F (Table 1); this profile is that of the internationally disseminated multiply resistant clone known as ‘Taiwan’[19,20] (ST236) [22] which is common in many parts of the world, including South East Asia, however isolates in our study were penicillin non-susceptible, erythromycin-resistant isolates. We also observed three isolates of the vaccine-related serotype 19A. This serotype has been observed to increase in prevalence in several countries following widespread use of PCV7, although there is some evidence for a modest cross-protective effect from the 19F component [29].

Of the ST we observed, four ST (ST 81, 83, 236, 458) have also been deposited on the database from other areas of Malaysia and since our analysis, ST3781 has been observed in two further Malaysian isolates and ST 3784 has been observed in India. A further five STs (ST 156, 236, 271, 458 and 4127) have been recorded from Singapore, Thailand or Vietnam.

ST31, 236 and 271 have been observed in Thailand [30] and in Singapore (ST31, 156, 199, 200, 236, 458, 3781) [31,32]. The most commonly deposited ST on the MLST database from ASEAN countries (those occurring with a frequency of five isolates or more) are shown in Table 2. These ST are associated with serogroups 15, 19 and 23; the latter two serogroups also rank highly among the 30 isolates examined here. It is not appropriate to make comparisons regarding serotype-ST associations between countries based on this data due to the way in which the MLST database is compiled; some researchers deposit only new STs, resulting in under-representation whereas others may upload data for all isolates in a collection, leading to over representation of clones common in particular collections.

The proportion of pneumococcal isolates in this study that would be covered by conjugate vaccines ranged from 57% for PCV7 and PHID-CV to 78% for PCV13. If cross protection against 6A is assumed this rises to 63% and 80% respectively. PCV7 was originally licensed on the ability to prevent invasive disease [33] but has also proved effective against pneumonia [34,35] and otitis media [36] as well as eliciting considerable herd immunity [13]. PHID-CV has been shown to protect against AOM caused by S. pneumoniae and non-typeable H. influenzae [37].

Although PCV13 and PHID-CV are indicated for prevention of invasive and non-invasive forms of pneumococcal disease [30], it is important to note that the isolates included in this study represent only IPD, were overwhelmingly from blood-stream isolates and were collected at one hospital during 2000–2007. While it is expected that use of PCVs in Malaysia would successfully reduce all forms of IPD caused by vaccine-serotypes, conclusions regarding vaccine coverage for meningitis and other forms of IPD cannot be directly drawn from this study. We therefore advocate further studies to investigate the serotype distribution, molecular epidemiology and antibiotic susceptibility of pneumococci causing other types of pneumococcal disease in Malaysia.

No penicillin resistant pneumococci were identified in this study, however 100% of penicillin-non susceptible isolates were of serotypes included in all three PCV. We cannot conclude that this level of coverage against penicillin non-susceptible pneumococci would be observed in other samples of disease-causing Malaysian pneumococci. It is also not appropriate to apply vaccine coverage estimates from this study to the wider Malaysian population.

As in many other countries worldwide, the prevalence of antibiotic-resistant pneumococci has been increasing in South East Asia over recent decades. The ANSORP Study Group has performed several surveillance studies designed to assess antimicrobial resistance of pneumococci in 12 South East Asian countries, including Malaysia, the results of which show that the prevalence of penicillin resistance among clinical isolates of S. pneumoniae has increased sharply from 3% during the period September 1996 to June 1997 to 29.5% in the period January 2000 to June 2001 [18]. More recent data from UMMC reported penicillin resistance among Malaysian clinical pneumococcal isolates to be 29.1%, with penicillin-non-susceptible isolates making up 50.3%, that study included pneumococcal isolates from both invasive and non-invasive disease [27]. In our study however, the proportion of penicillin-non-susceptible isolates was 33%. None of the isolates in our study exhibited an MIC of more than 1.0 mg/L; therefore 0% of our isolates were fully resistant to penicillin. Methods varied between the studies; we used E-test rather than the disc-diffusion method reported by Song et al. Both studies included small numbers of isolates (here n=30, ANSORP n=44). Small study size is likely to account for the differences in penicillin susceptibility we observed. Almost thirty percent of all the isolates included in this study (n=9) including 90% of the penicillin-non-susceptible pneumococci were also resistant to erythromycin, with MIC’s ranging from 2 mg/L to more than 256 mg/L, this is in accordance with the figure of 36.8% for pneumococci resistant to erythromycin [17].

The invasive potential of pneumococcal is linked not only to serotype but also to genotype [38–40]; the isolation of uncharacterised pneumococcal ST from blood CSF and pleural samples in Malaysia highlights the need for further studies especially when considering conjugate vaccine use. Surveillance of antimicrobial resistance, linked to good serotype and genotype data for pneumococci in Malaysia is important in order to determine the potential of any vaccine to reduce resistance rates as well as reducing mortality and morbidity from pneumococcal disease. Collection of genotype data is important in order to monitor the clonal distribution of the pneumococcal population. We and others [41] strongly recommend that further multi-centre studies employing MLST and serotyping to characterise both disease causing and carried pneumococci be performed in Malaysia. Such studies are required to track trends and provide good evidence on which to base policy decisions around the use of PCVs.

**Supporting Information**

Figure S1 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBURST (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink circles.). Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S1 shows CC199. (TIF)

Figure S2 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBURST (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink circles.). Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S2 shows CC81. (TIF)

Figure S3 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBURST (ST taken from the entire S. pneumoniae dataset...
Figure S4 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink circles. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S4 shows CC156.

Figure S5 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S5 shows CC473.

Figure S6 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S6 shows CC113.

Figure S7 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S7 shows CC221.

Figure S8 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S8 shows CC320.

Figure S9 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S9 shows CC2754.

Figure S10 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S10 shows CC1439.

Figure S11 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S11 shows CC3784.

Figure S12 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S12 shows CC180.

Figure S13 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S13 shows CC3442.

Figure S14 The fourteen clonal complexes (CC) into which ST identified in this study were assigned by eBurst (ST taken from the entire S. pneumoniae dataset at mlst.net accessed 30.07.2013). ST identified in this study are shown by pink text. Each black dot represents one ST. Dot sizes represent the number of isolates of a given ST. Lines join STs which share 6 of 7 loci. Blue dots indicate the estimated founders of CCs and yellow dots indicate sub-founders. Figure S14 shows CC458.

Acknowledgments

We acknowledge Elita Jauniekaite for helpful discussions. This publication made use of the Multi Locus Sequence Typing website (http://www.mlst.net) at Imperial College London developed by David Aanensen and funded by the Wellcome Trust.

Ethical Approval: Not Required.
Author Contributions
Conceived and designed the experiments: JMJ. Performed the experiments: JMJ. Analyzed the data: JMJ. Contributed reagents/}

References
1. Calix JJ, Dagan R, Peltola SI, Porat N, Nahm MH (2012) Differential Occurrence of Streptococcus pneumoniae Serotype 11E Between Asymptomatic Carriage and Invasive Pneumococcal Disease Isolates Reflects a Unique Model of Pathogen Microevolution. Clinical Infectious Diseases 54: 794–799.
2. Calix JJ, Nahm MH (2010) A New Pneumococcal Serotype, 11E, Has a Variously Inactivated wctE Gene. Journal of Infectious Diseases 202: 29–38.
3. Jin P, Kong F, Xiao M, Ofladeh S, Zhou F, et al. (2009) First Report of Putative Streptococcus pneumoniae Serotype 6D among Nasopharyngeal Isolates from Fijian Children. Journal of Infectious Diseases 200: 1375–1380.
4. Park IH, Pritchard DG, Carter R, Brandao A, Brandileone MC, et al. (2007) Discovery of a new capsular serotype (GC) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 45: 1225–1235.
5. Hausdorff WP, Bryant J, Paradis FR, Sipher GR (2008) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30: 100–121.
6. Desa MN, Lin TK, Yasim RM, Parasakthi N (2003) Penicillin susceptibility and molecular characteristics of clinical isolates of Streptococcus pneumoniae at the University of Malaya Medical Center, Kuala Lumpur, Malaysia. Int J Infect Dis 7: 190–197.
7. Jamal F, Pit S, Isahak I, Abdullah N, Zainal Z, et al. (1987) Pneumococcal infection in hospitalized patients: a four-year study in Malaysia. Southeast Asian J Trop Med Public Health 18: 79–84.
8. Rohani MY, Parasakthi N, Raudzah A, Yasim MY (1999) In-vitro susceptibilities of Streptococcus pneumoniae strains isolated in Malaysia to six antibiotics. J Antimicrob Chemother 44: 852–853.
9. Rohani MY, Raudzah A, Ng AJ, Ng PP, Zaidatul AA, et al. (1999) Epidemiology of Streptococcus pneumoniae infection in Malaysia. Epidemiol Infect 122: 77–82.
10. Rohani MY, Zin NM, Hussin A, Naswi SH, Hanapiah SM, et al. (2011) Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals. Vaccine 29: 5608–5609.
11. Jeevajothi Nathan J, Mohd Desa MN, Thong KI, Clarke SC, Masri SN, et al. (2014) Genotypic characterization of Streptococcus pneumoniae serotype 19F in Malaysia. Infect Genet Evol 21: 391–394.
12. Lim LH, Lee WS, Parasakthi N (2007) Childhood invasive pneumococcal disease: a hospital-based study from Malaysia. J Paediatr Child Health 43: 366–369.
13. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737–1746.
14. Isaacman DJ, McIntosh ED, Reidt RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Internation J Infectious Diseases 14: e197–e209.
15. Hausdorff WP, Feikin DR, Klagman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5: 83–93.
16. Hausdorff WP, Sipher G, Paradis PR (2001) Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357: 950–952.
17. Song JH, Chang HH, Suh JY, Ko KS, Jung SI, et al. (2004) Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J Antimicrob Chemother 53: 457–463.
18. Song JH, Jung SI, Ko KS, Kim NY, Son JS, et al. (2004) High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (in ANSORP study). Antimicrob Agents Chemother 48: 2101–2107.
19. Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, et al. (1999) Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP), Study. Clin Infect Dis 26: 1206–1211.
20. Pai R, Gerta RE, Beall B (2006) Sequential Multiplex PCR, Approach for Determining Capsular Serotypes of Streptococcus pneumoniae Isolates. J Clin Microbiol 44: 124–131.
21. Enright M, Spratt B (1998) A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144: 3049–3060.
22. Foel EJ, Li BC, Anzoune DM, Hanage WP, Spratt BG (2004) eBURST: Inferring Patterns of Evolutionary Descent among Clusters of Related Bacterial Genotypes from Multilocus Sequence Typing Data. J Bacterial 186: 1518–1530.
23. Jorgensen JH, Horswell AW, Maher LA (1991) Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the E-test. J Clin Microbiol 29: 109–114.
24. British Society for Antimicrobial Chemotherapy (2009) BSAC Methods for Antimicrobial Susceptibility Testing - Version 8 January 2009.
25. Jassekeita E, Jeffries JM, Hibberd ML, Clarke SC (2012) Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine 30: 5303–5314.
26. Le CF, Jeffries JM, Yusof MY, Sekaran SD, Clarke SC (2012) The epidemiology of pneumococcal carriage and infections in Malaysia. Expert Rev Anti Infect Ther 10: 707–719.
27. Le CF, Palanisamy NK, Mohd Yusof MY, Sekaran SD (2011) Capsular serotype and antibiotic resistance of Streptococcus pneumoniae isolates in Malaysia. Plos ONE 6: e19547.
28. Shi ZY, Enright MC, Wilkinson P, Griffiths D, Spratt BG (1998) Identification of Three Major Clones of Multiply Antibiotic-Resistant Streptococcus pneumoniae in Taiwanese Hospitals by Multilocus Sequence Typing. Journal of Clinical Microbiology: 36: 3514–3519.
29. Hausdorff WP, Hoet B, Schuurman L (2010) Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 10: 4.
30. Schultz C, Vien le M, Campbell J, Chau NV, Depf TS, et al. (2007) Changes in the nasal carriage of drug-resistant Streptococcus pneumoniae in urban and rural Vietnamese schoolchildren. Trans R Soc Trop Med Hyg 101: 494–492.
31. Jeffries JM, Tee WS, Clarke SC (2011) Molecular analysis of Streptococcus pneumoniae clones causing invasive disease in children in Singapore. J Med Microbiol 60: 730–735.
32. Jassekeita E, Churton N, Lin R, Jeffries JM, Hibberd M, et al. (2012) Prevalence of serotypes and molecular types among Streptococcus pneumoniae isolates causing invasive disease in Singapore between June 2008 and August 2010. 15th International Conference on Infectious Diseases, June 13–16 2012. Bankok, Thailand.
33. CDC (2000) Preventing Pneumococcal Disease Among Infants and Young Children. Morbidity and Mortality Weekly Report 49: 1–38.
34. Black SB, Sharonfield HR, Ling S, Hansen J, Fireman B, et al. (2002) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatric Infectious Disease Journal 21: 810–815.
35. Lucero MG, Dalalae VE, Nillos LT, Williams G, Parreno RA, et al. (2009) Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and Xevi defined pneumonia in children less than two years of age. Cochrane Database Syst Rev: CD004977.
36. Palmo AA, Verho J, Jokinen J, Karma F, Kilpi TM (2004) The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatric Infectious Disease Journal 23: 732–738.
37. Prumila R, Peters P, Chrobok V, Kriz P, Novakova E, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367: 740–746.
38. Syos memorandum C, Spinder C, Otvospt C, Kalion M, Sandgren A, et al. (2006) Clonal and capsular type decisions which pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 42: 451–459.
39. Hanage WP, Kaajalainen TH, Syrjanen RK, Auranen K, Leinonen M, et al. (2005) Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun 73: 431–435.
40. Kirkham IA, Jeffries JM, Kerr AR, Jing Y, Clarke SC, et al. (2006) Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin. J Clin Microbiol 44: 151–159.
41. Bravo LG (2009) Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 27: 7282–7291.